Objective
Systemic autoinflammatory diseases (SAID) encompass several rare disorders characterised by extensive clinical and biological inflammation. SAID are caused by the dysregulation of the innate immune system. Due to numerous and unspecific symptoms, tentative diagnosis often leads to failure/delay and inadequate treatments. ImmunAID will deliver a method for rapid and accurate diagnosis across all the spectrum of SAID, in order to improve clinical management of SAID patients. Thanks to parallel analyses run on samples from more than 600 patients with monogenic or undiagnosed SAID collected throughout Europe, Immunaid will generate a unique and comprehensive set of data, based on unbiased multiomics approaches (gene, transcript, protein, microbiome), and hypothesis-driven assays exploring inflammasome, inflammation resolution and immune networks. A centralised data management strategy will enable to conduct integrated analyses for diagnostic biomarker identification. In a discovery phase, semi-supervised clustering of omics data will be combined to supervised analysis of pathway-related data to provide robust classification and strong link to clinical features/impact. The related biomarkers will further be validated externally on independent samples and cohorts. Overall, ImmunAID will disentangle the spectrum of SAID, and propose a new omics- and pathogenesis-based SAID classification associated to a clinical decision making algorithm implementable in daily practice. An efficient dissemination plan will target e.g. guideline-forming bodies, the medical community and patients with the help of the ERN RITA and with the objective of turning our results into clinical practice. To further support this, proactive innovation management will be implemented. To reach its ambitious goals, ImmunAID interdisciplinary consortium gathers high-level partners, including the founder of SAID concept, experts in omics science, immunology, bioinformatics, and involves clinicians and patient advocacy groups.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
75654 Paris
France
See on map
Participants (26)
75000 Paris
See on map
9052 Zwijnaarde - Gent
See on map
3000 Leuven
See on map
4000 Liege
See on map
1165 Kobenhavn
See on map
75231 Paris
See on map
75010 Paris
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
31400 Toulouse
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
48149 Muenster
See on map
115 27 Athina
See on map
3015 GD Rotterdam
See on map
1211 Geneve
See on map
LS2 9JT Leeds
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
LS9 7TF Leeds
See on map
WC1E 6BT London
See on map
45110 Ioannina
See on map
4000 Liege
See on map
8306 Bruttisellen
See on map
06800 Cankaya Ankara
See on map
1000 Ljubljana
See on map
08950 Esplugues De Llobregat
See on map
00165 Roma
See on map
75015 Paris 15
See on map
75013 Paris
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1445 Strassen
See on map
31320 Castanet-tolosan
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.